公司介绍 - ANI Pharmaceuticals, Inc.宣布首席执行官Nikhil Lalwani和首席财务官Stephen Carey将在Leerink Partners Global Biopharma Conference上发表演讲[1] - ANI Pharmaceuticals, Inc.是一家多元化的生物制药公司，致力于为患者提供高质量的品牌和仿制处方药产品，包括治疗高度未满足医疗需求的疾病[3] 联系信息 - 投资者关系联系人是Lisa M. Wilson，In-Site Communications, Inc.，联系电话为212-452-2793，电子邮件为lwilson@insitecony.com[4]

股价表现 - ANI Pharmaceuticals (ANIP) 最新收盘价为 $57.03，较上一交易日上涨了 +0.92% [1] - ANI Pharmaceuticals (ANIP) 过去一个月股价下跌了 0.41%，落后于医疗行业的涨幅 2.32% 和标普500指数的涨幅 5.78% [2] 财务预期 - ANI Pharmaceuticals (ANIP) 即将发布财报，预计每股收益为 $0.78，同比增长 2.63%，预计营收为 $119.38 百万美元，同比增长 26.69% [3] 分析师预期 - 分析师对 ANI Pharmaceuticals (ANIP) 的预期发生了变化，这些变化通常反映了最新的短期业务趋势 [4]

BAUDETTE, Minn., Feb. 07, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its fourth quarter and full year 2023 financial results on Thursday, February 29, 2024, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows: Date Thursday, February 29, 2024    ...

The most recent trading session ended with ANI Pharmaceuticals (ANIP) standing at $56.04, reflecting a +1.12% shift from the previouse trading day's closing. The stock's change was more than the S&P 500's daily loss of 0.32%. On the other hand, the Dow registered a loss of 0.71%, and the technology-centric Nasdaq decreased by 0.2%.Heading into today, shares of the drugmaker had lost 2.38% over the past month, lagging the Medical sector's gain of 2.33% and the S&P 500's gain of 4.59% in that time.Investors w ...

In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $55.02, marking a +0.7% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.76%. Meanwhile, the Dow experienced a rise of 0.59%, and the technology-dominated Nasdaq saw an increase of 1.12%.Prior to today's trading, shares of the drugmaker had lost 0.91% over the past month. This has lagged the Medical sector's gain of 1.57% and the S&P 500's gain of 2.5% in that time.The investment community will be ...

公司活动 - ANI Pharmaceuticals, Inc.宣布首席执行官Nikhil Lalwani将参加Guggenheim Healthcare Talks | 第六届生物技术年会的炉边聊天[1] - 会议将于2024年2月8日星期四举行，东部时间上午10:30[2] - 可通过公司网站www.anipharmaceuticals.com在投资者部分的活动和演示下访问现场和存档的网络研讨会[3]

BAUDETTE, Minn., Jan. 23, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the launch of Pentoxifylline Extended-Release (ER) Tablets, USP 400mg. ANI's Pentoxifylline ER Tablets are the generic version of the Reference Listed Drug (RLD) Trental®. The current annual U.S. market for Pentoxifylline ER Tablets is approximately $19.7 million, according to latest estimates from IQVIA/IMS Health, a leading healthcare data and analytics provider. "We are pleased ...

股价表现 - ANI Pharmaceuticals (ANIP) 最近的交易日收盘价为 $56.17，较前一个交易日上涨了 +1.37% [1] - ANIP 股价在过去一个月上涨了 3.71%，超过了医疗行业的涨幅 2.3% 和标普500指数的涨幅 1.61% [2] 财务表现 - ANI Pharmaceuticals 预计将公布每股收益为 $0.78，比去年同期增长了 2.63%。同时，最新的共识估计显示公司预计营收为 $119.38 百万美元，比去年同期增长了 26.69% [3] 分析师关注点 - 分析师和投资者将密切关注 ANI Pharmaceuticals 在即将公布的财报中的表现 [3] - 投资者应关注分析师对 ANI Pharmaceuticals 的最新估值变化，这些变化通常反映了最新的短期业务趋势 [4] 市场评级 - ANI Pharmaceuticals 目前的前瞻市盈率为 13.65，低于行业平均前瞻市盈率 22.43 [7] 行业排名 - 医疗 - 生物医学和遗传学行业属于医疗行业，目前的 Zacks 行业排名为 96，在所有 250+ 个行业中处于前 39% [8] - Zacks 行业排名通过测量组内个别股票的平均 Zacks 排名来衡量我们各个行业群体的实力 [9]

股价表现 - ANI Pharmaceuticals (ANIP) 最近收盘价为$55.41，较前一个交易日下跌了0.32% [1] - ANI Pharmaceuticals 过去一个月股价上涨了4.63%，医疗行业上涨了3.16%，而标普500指数上涨了0.94% [2] 财务表现 - ANI Pharmaceuticals 预计将在即将发布的财报中报告每股收益为$0.78，同比增长2.63%，预计营收为$119.38百万美元，同比增长26.69% [3] - ANI Pharmaceuticals 的前瞻市盈率为13.69，低于行业平均值22.48，意味着公司的股价折价于行业 [7] 分析评级 - 分析师对 ANI Pharmaceuticals 的估值发生了变化，这反映了近期业务趋势的不断变化 [4] - ANI Pharmaceuticals 目前的 Zacks Rank 为 3 (Hold)，过去一个月 Zacks Consensus EPS 估计没有变化 [6] 行业评级 - 医疗 - 生物医学和遗传学行业属于医疗行业，目前的 Zacks Industry Rank 为89，在所有250+个行业中排名前36% [8] - Zacks Industry Rank 通过计算各个股票的平均 Zacks Rank 来评估行业群体的实力，研究表明排名前50%的行业的表现是排名后50%的两倍 [9] 其他信息 - Zacks Rank 模型考虑了这些估值变化，并提供了一个可操作的评级系统 [5] - 在 Zacks.com 上可以关注所有这些影响股价的指标以及更多信息 [10]

BAUDETTE, Minn., Jan. 16, 2024 (GLOBE NEWSWIRE) --  ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Indomethacin Oral Suspension (OS), USP. ANI's Indomethacin OS is the generic version of the Reference Listed Drug (RLD) Indocin® Oral Suspension. The current annual U.S. market for Indomethacin OS is approximately $4.1 million, according to the latest estimates fro ...